Tumor volume in insignificant prostate cancer: Increasing threshold gains increasing risk

@article{Schiffmann2015TumorVI,
  title={Tumor volume in insignificant prostate cancer: Increasing threshold gains increasing risk},
  author={Jonas Schiffmann and Judith Connan and Georg Salomon and Katharina Boehm and Burkhard Beyer and Thorsten Schlomm and Pierre Tennstedt and Guido Sauter and Pierre I Karakiewicz and Markus Graefen and Hartwig Huland},
  journal={The Prostate},
  year={2015},
  volume={75}
}
An increased tumor volume threshold (<2.5 ml) is suggested to define insignificant prostate cancer (iPCa). We hypothesize that an increasing tumor volume within iPCa patients increases the risk of biochemical recurrence (BCR) after radical prostatectomy (RP). 
View on Wiley
ediss.sub.uni-hamburg.de
20 Citations
Background Citations
2
Methods Citations
1

20 Citations

Citation Type

Citation Type

Tumor volume in insignificant prostate cancer: Increasing the threshold is a safe approach to reduce over‐treatment
TLDR
This study retrospectively evaluates the association of an increasing TV with biochemical recurrence (BCR) following radical prostatectomy (RP) in order to provide further clarification surrounding the TV threshold definition for insignificant PCa.
Identification of pathologically favorable disease in intermediate‐risk prostate cancer patients: Implications for active surveillance candidates selection
TLDR
A model for the identification of pathologically favorable PCa at radical prostatectomy (RP) among intermediate‐risk patients is developed.
Prostate cancer: Is prostatectomy for Gleason score 6 a treatment failure?
The contemporary plea for a more liberal pathological definition of insignificant prostate cancer was recently challenged by Schiffmann and colleagues, who advocate a return to the original,…
Clinically insignificant prostate cancer suitable for active surveillance according to Prostate Cancer Research International: Active surveillance criteria: Utility of PI‐RADS v2
TLDR
Few studies have reported the value of PI‐RADS v2 for assessing risk stratification in patients with PCa, especially on selecting potential candidates for AS.
Extensive disease among potential candidates for hemi‐ablative focal therapy for prostate cancer
  • T. Takeda, A. Tin, +14 authors K. Touijer
  • Medicine
    International journal of urology : official journal of the Japanese Urological Association
  • 2019
To examine a set of proposed eligibility factors for hemi‐ablative focal therapy in prostate cancer and to determine the likelihood of residual extensive disease.
Defining clinically significant prostate cancer on the basis of pathological findings
TLDR
Much research has been carried out to better define significant/insignificant cancer, in order to be able to safely offer AS to a larger proportion of patients without the risk of undertreatment, and research has focused on allowing higher volume tumours, focal extraprostatic extension, and a limited amount of Gleason pattern 4.
Definition of Insignificant Tumor Volume of Gleason Score 3 + 3 = 6 (Grade Group 1) Prostate Cancer at Radical Prostatectomy-Is it Time to Increase the Threshold?
Do tumor volume, percent tumor volume predict biochemical recurrence after radical prostatectomy? A meta-analysis.
TLDR
It is demonstrated that both TV and PTV were significantly associated with BCR after RP, and should be considered when assessing the risk of BCR in RP specimens.
Clinical and molecular rationale to retain the cancer descriptor for Gleason score 6 disease
TLDR
Molecular data suggest that the genomic instability underlying tumour progression precedes histologically visible changes and the absolute risk of metastasis or mortality from Gleason score 6 prostate cancer is not zero, so extreme caution is required when weighing a decision to reclassify Gleason pattern 3 disease as a non-cancer.
Controversial evidence for the use of HistoScanning™ in the detection of prostate cancer
TLDR
High sensitivity and specificity for HistoScanning™ to predict cancer foci ≥0.5 ml at final pathology were achieved in the pilot study, but results were questioned, when Histo Scanning™ derived tumor volume does not correlate with final pathology results.
...
1
2
...

References

SHOWING 1-10 OF 14 REFERENCES
Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer
TLDR
The authors calculated the probability at birth of having a diagnosis of prostate cancer within a man's life to be 8.8% and subtracted the incidence of microscopic Stage A cancers too small to ever be clinically significant.
After radical retropubic prostatectomy ‘insignificant’ prostate cancer has a risk of progression similar to low‐risk ‘significant’ cancer
TLDR
To assess progression and survival among patients with small‐volume, well‐differentiated, organ‐confined prostate cancer found at radical retropubic prostatectomy (RRP), testing whether they are indeed ‘insignificant’ is tested.
Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy
TLDR
The authors studied the correlation between the visual estimate of the percentage of carcinoma in prostatic tissue from radical prostatectomy specimens and prostate carcinoma recurrence rates in a series of 595 patients who underwent radical prostateCTomy.
A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial.
Biochemical outcome of small-volume or insignificant prostate cancer treated with radical prostatectomy in Japanese population
TLDR
Despite the limited number of cases, patients with InsigCa did not develop BCR whereas 12.9% of those with SVCa developed BCR after radical prostatectomy within 5 years, indicating accurate prediction of the biochemical outcome of SVC a remains difficult and further studies are needed.
The contemporary concept of significant versus insignificant prostate cancer.
Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.
TLDR
Serum PSA level, PSA density, and needle biopsy pathologic findings are accurate predictors of tumor extent and it may be reasonable to follow up some patients whose tumors are most likely insignificant with serial PSA measurements and repeated biopsies.
Assessment of biochemical recurrence rate in patients with pathologically confirmed insignificant prostate cancer.
Predictive factors of oncologic outcomes in patients who do not achieve undetectable prostate specific antigen after radical prostatectomy.
Natural history of progression after PSA elevation following radical prostatectomy.
TLDR
Several clinical parameters help predict the outcomes of men with PSA elevation after radical prostatectomy, and these data may be useful in the design of clinical trials, the identification of men for enrollment into experimental protocols, and counseling men regarding the timing of administration of adjuvant therapies.
...
1
2
...